MX358499B - Moduladores de dihidropirazol del receptor acoplado a la proteína g (gpr40). - Google Patents

Moduladores de dihidropirazol del receptor acoplado a la proteína g (gpr40).

Info

Publication number
MX358499B
MX358499B MX2015005735A MX2015005735A MX358499B MX 358499 B MX358499 B MX 358499B MX 2015005735 A MX2015005735 A MX 2015005735A MX 2015005735 A MX2015005735 A MX 2015005735A MX 358499 B MX358499 B MX 358499B
Authority
MX
Mexico
Prior art keywords
gpr40 modulators
dihydropyrazole
dihydropyrazole gpr40
modulators
compounds
Prior art date
Application number
MX2015005735A
Other languages
English (en)
Other versions
MX2015005735A (es
Inventor
R Ewing William
s hernandez Andres
A Allsworth Bruce
Shi Jun
A Jurica Elizabeth
Wu Ximao
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MX2015005735A publication Critical patent/MX2015005735A/es
Publication of MX358499B publication Critical patent/MX358499B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Optical Integrated Circuits (AREA)

Abstract

La presente invención proporciona compuestos de la Fórmula (I): o un estereoisómero o una sal farmacéuticamente aceptable del mismo, en donde todas las variables son como se definen en la presente. Estos compuestos son moduladores del receptor acoplado a la proteína GPR4O G, que se pueden usar como medicamentos.
MX2015005735A 2012-11-16 2013-11-15 Moduladores de dihidropirazol del receptor acoplado a la proteína g (gpr40). MX358499B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261727262P 2012-11-16 2012-11-16
US201361777294P 2013-03-12 2013-03-12
PCT/US2013/070215 WO2014078610A1 (en) 2012-11-16 2013-11-15 Dihydropyrazole gpr40 modulators

Publications (2)

Publication Number Publication Date
MX2015005735A MX2015005735A (es) 2015-09-16
MX358499B true MX358499B (es) 2018-08-23

Family

ID=49876965

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015005735A MX358499B (es) 2012-11-16 2013-11-15 Moduladores de dihidropirazol del receptor acoplado a la proteína g (gpr40).

Country Status (26)

Country Link
US (1) US9133163B2 (es)
EP (1) EP2920165B1 (es)
JP (1) JP6322203B2 (es)
KR (1) KR102204804B1 (es)
CN (1) CN104812748B (es)
AU (1) AU2013344604B2 (es)
BR (1) BR112015010779A2 (es)
CA (1) CA2891574A1 (es)
CY (1) CY1118365T1 (es)
DK (1) DK2920165T3 (es)
EA (1) EA026913B1 (es)
ES (1) ES2606685T3 (es)
HR (1) HRP20161631T1 (es)
HU (1) HUE032401T2 (es)
IL (1) IL238741A0 (es)
LT (1) LT2920165T (es)
MX (1) MX358499B (es)
PL (1) PL2920165T3 (es)
PT (1) PT2920165T (es)
RS (1) RS55363B1 (es)
SG (1) SG11201503558SA (es)
SI (1) SI2920165T1 (es)
SM (1) SMT201600410B (es)
TW (1) TW201427971A (es)
UY (1) UY35143A (es)
WO (1) WO2014078610A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2015005858A (es) * 2012-11-16 2015-09-24 Bristol Myers Squibb Co Moduladores del receptor acoplado a proteina g (gpr40) de dihidropirazol.
AU2014372114A1 (en) 2013-11-14 2016-06-09 Cadila Healthcare Limited Novel heterocyclic compounds
AR100328A1 (es) 2014-05-07 2016-09-28 Bristol Myers Squibb Co Moduladores pirrolidina de gpr40
US10017497B2 (en) * 2014-05-07 2018-07-10 Bristol-Myers Squibb Company Pyrrolidine GPR40 modulators for the treatment of diseases such as diabetes
WO2016019587A1 (en) 2014-08-08 2016-02-11 Merck Sharp & Dohme Corp. [7, 6]-fused bicyclic antidiabetic compounds
US10968193B2 (en) 2014-08-08 2021-04-06 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
US10100042B2 (en) 2014-08-08 2018-10-16 Merck Sharp & Dohme Corp. [5,6]—fused bicyclic antidiabetic compounds
EP3177282B1 (en) 2014-08-08 2021-10-06 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
JPWO2018181847A1 (ja) 2017-03-31 2020-03-05 武田薬品工業株式会社 芳香環化合物
WO2019160882A1 (en) 2018-02-13 2019-08-22 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
WO2019204609A1 (en) 2018-04-19 2019-10-24 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
BR112020026746A2 (pt) 2018-07-13 2021-03-30 Gilead Sciences, Inc. Composto, composição farmacêutica, métodos para inibir pd-1, pd-l1 e/ou a interação de pd-1/pd-l1 e para tratar câncer, e, kit para tratar ou prevenir câncer ou uma doença ou condição.
CN112955435B (zh) 2018-10-24 2024-09-06 吉利德科学公司 Pd-1/pd-l1抑制剂
CN115490638A (zh) * 2022-09-22 2022-12-20 哈尔滨理工大学 5-官能团化吡唑啉及其制备方法
CN115671105B (zh) * 2022-11-22 2023-10-27 北京箭牧科技有限公司 Ly2922470在制备预防或治疗肾脏疾病药物中的应用
CN119431272B (zh) * 2024-11-13 2025-07-25 北京斯利安药业有限公司 （s）-3-甲基-（2-哌啶基苯基）-1-丁胺乙酰谷氨酸盐的制备方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5614492A (en) 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
WO2003099793A1 (en) 2002-05-24 2003-12-04 Takeda Pharmaceutical Company Limited 1,2-azole derivatives with hypoglycemic and hypolipidemic activity
WO2004004665A2 (en) 2002-07-09 2004-01-15 Bristol-Myers Squibb Company Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method
US7501440B2 (en) 2003-03-07 2009-03-10 Sanofi-Aventis Deutschland Gmbh Substituted benzoylureidopyridylpiperidine-and-pyrrolidinecarboxylic acid derivatives, processes for preparing them and their use
US6995183B2 (en) 2003-08-01 2006-02-07 Bristol Myers Squibb Company Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods
EP1637522A1 (en) 2004-09-16 2006-03-22 Laboratorios Del Dr. Esteve, S.A. Substituted pyrazoline compounds for reducing triglycerides in blood
RU2006133260A (ru) * 2004-02-17 2008-04-10 Лабораториос Дель Др. Эстеве С.А. (Es) Соединения замещенного пиразолина, их получение и применение в качестве лекарственных средств
EA011010B1 (ru) 2004-02-27 2008-12-30 Эмджен, Инк. Соединения, модулирующие рецептор gpr40, фармацевтическая композиция, способ лечения заболеваний, чувствительных к модулированию рецептора gpr40 (варианты), способ модулирования функции gpr40 (варианты) и способ модулирования циркулирующей концентрации инсулина
EP1731505B1 (en) 2004-03-30 2015-01-14 Takeda Pharmaceutical Company Limited Alkoxyphenylpropanoic acid derivatives
JP2007284350A (ja) 2004-07-27 2007-11-01 Takeda Chem Ind Ltd 糖尿病治療剤
US7465804B2 (en) 2005-05-20 2008-12-16 Amgen Inc. Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders
EP1743894A1 (en) * 2005-07-15 2007-01-17 Laboratorios Del Dr. Esteve, S.A. Heterocyclyl-substituted pyrazoline compounds, their preparation and use as medicaments
JP5084503B2 (ja) 2005-07-29 2012-11-28 武田薬品工業株式会社 シクロプロパンカルボン酸化合物
WO2007033002A1 (en) 2005-09-14 2007-03-22 Amgen Inc. Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders
CA2646430A1 (en) 2006-03-14 2007-09-20 Amgen Inc. Bicyclic carboxylic acid derivatives useful for treating metabolic disorders
ES2379661T3 (es) 2006-06-27 2012-04-30 Takeda Pharmaceutical Company Limited Compuestos cíclicos condensados
CA2662305C (en) 2006-09-07 2012-04-17 Amgen Inc. Heterocyclic gpr40 modulators
US8039484B2 (en) 2006-10-31 2011-10-18 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
US7572934B2 (en) 2007-04-16 2009-08-11 Amgen Inc. Substituted biphenyl GPR40 modulators
BRPI0818253A2 (pt) 2007-10-10 2015-04-07 Amgen Inc Moduladores de gpr40 bifenil substituídos
AR071055A1 (es) 2007-10-26 2010-05-26 Japan Tobacco Inc Compuestos espiro, composiciones farmaceuticas y medicamentos que los comprenden, agente promotor de la secrecion de insulina y usos para la preparacion de medicamentos y composiciones farmaceuticas
AR070898A1 (es) * 2008-03-18 2010-05-12 Solvay Pharm Bv Derivados de arilsulfonil pirazolin carboxamidina como antagonistas de 5-ht6
US8236821B2 (en) * 2008-05-19 2012-08-07 Jenrin Discovery, Inc. Substituted N-phenyl-5-phenyl-pyrazolin-3-yl amides as cannabinoid receptor antagonists/inverse agonists useful for treating obesity
AU2010303670A1 (en) * 2009-10-06 2012-03-29 Bristol-Myers Squibb Company Pyrrolidine GPR40 modulators
AR078522A1 (es) 2009-10-15 2011-11-16 Lilly Co Eli Compuesto de espiropiperidina, composicion farmaceutica que lo comprende, su uso para preparar un medicamento util para tratar diabetes y compuesto intermediario para su sintesis
US8580768B2 (en) * 2010-11-18 2013-11-12 Jenrin Discovery, Inc. Cannabinoid receptor antagonists-inverse agonists useful for treating metabolic disorders, including obesity and diabetes
CA2818050A1 (en) * 2010-11-26 2012-05-31 Lupin Limited Bicyclic gpr119 modulators
US8791091B2 (en) 2011-12-02 2014-07-29 Bristol-Myers Squibb Company Aryl dihydropyridinone and piperidinone MGAT2 inhibitors
US9326218B2 (en) * 2012-11-02 2016-04-26 Telefonaktiebolaget L M Ericsson (Publ) Base-station-to-base-station gateway and related devices, methods, and systems
MX2015005858A (es) * 2012-11-16 2015-09-24 Bristol Myers Squibb Co Moduladores del receptor acoplado a proteina g (gpr40) de dihidropirazol.
US8962660B2 (en) * 2013-03-14 2015-02-24 Bristol-Myers Squibb Company Oxabicyclo [2.2.2] acid GPR120 modulators

Also Published As

Publication number Publication date
SG11201503558SA (en) 2015-06-29
LT2920165T (lt) 2016-12-12
JP6322203B2 (ja) 2018-05-09
SMT201600410B (it) 2017-01-10
KR102204804B1 (ko) 2021-01-18
PL2920165T3 (pl) 2017-04-28
RS55363B1 (sr) 2017-03-31
CN104812748A (zh) 2015-07-29
MX2015005735A (es) 2015-09-16
HRP20161631T1 (hr) 2017-01-13
US20140142139A1 (en) 2014-05-22
HUE032401T2 (en) 2017-09-28
ES2606685T3 (es) 2017-03-27
WO2014078610A1 (en) 2014-05-22
EP2920165A1 (en) 2015-09-23
UY35143A (es) 2014-05-30
PT2920165T (pt) 2016-12-20
TW201427971A (zh) 2014-07-16
CN104812748B (zh) 2017-10-24
BR112015010779A2 (pt) 2017-07-11
EP2920165B1 (en) 2016-09-28
KR20150082616A (ko) 2015-07-15
IL238741A0 (en) 2015-06-30
AU2013344604B2 (en) 2017-07-27
DK2920165T3 (en) 2017-01-16
CY1118365T1 (el) 2017-06-28
EA026913B1 (ru) 2017-05-31
CA2891574A1 (en) 2014-05-22
US9133163B2 (en) 2015-09-15
EA201590954A1 (ru) 2015-08-31
SI2920165T1 (sl) 2017-02-28
JP2016500063A (ja) 2016-01-07
AU2013344604A1 (en) 2015-07-02

Similar Documents

Publication Publication Date Title
MX2015005858A (es) Moduladores del receptor acoplado a proteina g (gpr40) de dihidropirazol.
MX2015005735A (es) Moduladores de dihidropirazol de receptor acoplado a la proteona g (gpr40).
MX2015005720A (es) Moduladores de dihidropirazol de receptor acoplado a la proteina g (gpr40).
MX2012003389A (es) Moduladores de gpr40 de pirrolidina.
PH12016500777A1 (en) Compositions and methods for modulating farnesoid x receptors
EA201591805A1 (ru) Оксабицикло [2.2.2] кислоты - модуляторы gpr120
IN2014CN03803A (es)
TN2014000030A1 (en) Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as c5a receptor modulators
AU2015328174A8 (en) Modulators of cystic fibrosis transmembrane conductance regulator
MY181959A (en) Pyrrolidine gpr40 modulators for the treatment of diseases such as diabetes
EA201590953A1 (ru) Пирролидиновые модуляторы gpr40
MY170713A (en) Treatment protocol of diabetes type 2
IN2015DN00598A (es)
MY187718A (en) Pharmaceutical formulations
MY197698A (en) Oxysterols and methods of use thereof
EA201591815A1 (ru) Бицикло [2.2.2] кислоты - модуляторы gpr120
MX2015015562A (es) Dihidropiridinona como inhibidores de monoacilglicerol aciltransferasa 2.
WO2014159794A3 (en) Bicyclo [2.2.1] acid gpr120 modulators
PH12016501517A1 (en) Tetrazolone-substituted dihydropyridinone mgat2 inhibitors
MX2016011105A (es) Inhibidores de monoacilglicerol aciltransferasa 2 (mgat2) de dihidropiridinona para usarse en el tratamiento de trastornos metabolicos.
MX362879B (es) Usos novedosos.
IN2014DN07996A (es)
MX2016014118A (es) Moduladores de receptor de proteina g 40 (gpr40) de pirrolidina para tratamiento de enfermedades tales como diabetes.
MX2016005287A (es) Metodos para el tratamiento de distrofias musculares.
MA40320A (fr) Agent prophylactique ou thérapeutique pour des troubles du segment postérieur de l&#39;œil

Legal Events

Date Code Title Description
FG Grant or registration